- Home
- CENN vs LGVN Comparison
CENN vs LGVN Comparison
Compare CENN & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENN
- LGVN
- Stock Information
- Founded
- CENN 2013
- LGVN 2014
- Country
- CENN United States
- LGVN United States
- Employees
- CENN N/A
- LGVN N/A
- Industry
- CENN Auto Manufacturing
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- CENN Consumer Discretionary
- LGVN Health Care
- Exchange
- CENN Nasdaq
- LGVN Nasdaq
- Market Cap
- CENN 28.3M
- LGVN 27.6M
- IPO Year
- CENN N/A
- LGVN 2021
- Fundamental
- Price
- CENN $0.83
- LGVN $1.56
- Analyst Decision
- CENN
- LGVN Strong Buy
- Analyst Count
- CENN 0
- LGVN 3
- Target Price
- CENN N/A
- LGVN $8.67
- AVG Volume (30 Days)
- CENN 142.4K
- LGVN 201.8K
- Earning Date
- CENN 05-11-2025
- LGVN 05-13-2025
- Dividend Yield
- CENN N/A
- LGVN N/A
- EPS Growth
- CENN N/A
- LGVN N/A
- EPS
- CENN N/A
- LGVN N/A
- Revenue
- CENN $31,297,393.00
- LGVN $2,392,000.00
- Revenue This Year
- CENN N/A
- LGVN $26.05
- Revenue Next Year
- CENN N/A
- LGVN $12.27
- P/E Ratio
- CENN N/A
- LGVN N/A
- Revenue Growth
- CENN 142.48
- LGVN 237.38
- 52 Week Low
- CENN $0.64
- LGVN $0.77
- 52 Week High
- CENN $2.30
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- CENN 40.85
- LGVN 45.61
- Support Level
- CENN $0.86
- LGVN $1.44
- Resistance Level
- CENN $0.98
- LGVN $1.62
- Average True Range (ATR)
- CENN 0.07
- LGVN 0.12
- MACD
- CENN -0.01
- LGVN -0.02
- Stochastic Oscillator
- CENN 4.53
- LGVN 25.00
About CENN Cenntro Electric Group Limited
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles. Its vehicles include Metro, Logistar 400, Logistar 200, Neibor 200, and ORV. The company's geographical segments include Europe, America, and Asia.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.